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Psychosis has been proposed to develop from dysfunction in a hippocampal-striatal-
midbrain circuit, leading to aberrant salience processing. Here, we used functional 
magnetic resonance imaging (fMRI) during novelty salience processing to investigate 
this model in people at clinical high-risk (CHR) for psychosis according to their 
subsequent clinical outcomes. Seventy-six CHR participants as defined using the 
Comprehensive Assessment of At-Risk Mental States (CAARMS) and 31 healthy 
controls (HC) were studied while performing a novelty salience fMRI task that 
engaged an a priori hippocampal-striatal-midbrain circuit of interest. The CHR 
sample was then followed clinically for a mean of 59.7 months (~5 years), when 
clinical outcomes were assessed in terms of transition (CHR-T) or non-transition 
(CHR-NT) to psychosis (CAARMS criteria): during this period, 13 individuals (17%) 
developed a psychotic disorder (CHR-T) and 63 did not. Functional activation and 
effective connectivity within a hippocampal-striatal-midbrain circuit were compared 
between groups. In CHR individuals compared to HC, hippocampal response to 
novel stimuli was significantly attenuated (P=0.041 family-wise error corrected). 
Dynamic Causal Modelling revealed that stimulus novelty modulated effective 
connectivity from the hippocampus to the striatum, and from the midbrain to the 
hippocampus, significantly more in CHR participants than in HC. Conversely, 
stimulus novelty modulated connectivity from the midbrain to the striatum significantly 
less in CHR participants than in HC, and less in CHR participants who subsequently 
developed psychosis than in CHR individuals who did not become psychotic. Our 
findings are consistent with preclinical evidence implicating hippocampal-striatal-
midbrain circuit dysfunction in altered salience processing and the onset of 
psychosis.  
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INTRODUCTION 
The inappropriate attribution of salience to what would normally be irrelevant or 
neutral stimuli is a robust feature of psychotic disorders, and is linked to altered 
subcortical dopaminergic signaling1, 2. Whilst there are a number of animal models 
that attempt to describe the pathology and development of psychosis (e.g., chronic 
phencyclidine models, prenatal immune activation models (for review, see 3), a 
particularly influential model proposes that psychosis develops when hippocampal 
dysfunction drives increased subcortical dopamine activity through descending 
projections to the striatum.4, 5 Neuroimaging studies of reward salience suggest that 
salience processing and associated neural hippocampal-striatal-midbrain responses 
are perturbed in both patients with psychosis6, 7 and individuals at clinical high-risk 
(CHR) for psychosis8-11, and that this is associated with positive symptoms11. In this 
context, although novelty has been less investigated as a dimension of salience than 
reward in psychosis12, preclinical evidence indicates that dopaminergic neurons in 
the midbrain code the salience of unexpected stimuli and respond to novel stimuli13, 
14. The first aim of the present study was to examine hippocampal-striatum-midbrain 
circuit activation and effective connectivity in CHR individuals. We assessed 
activation using functional magnetic resonance imaging (fMRI) in conjunction with a 
novelty salience paradigm based on a task that had previously elicited robust 
hippocampal-striatal-midbrain responses15, and employed Dynamic Casual Modeling 
(DCM)16 to assess effective connectivity within this circuit.  
 
While previous neuroimaging studies had reported altered activation and 
connectivity in a hippocampal-striatal-midbrain circuit during reward salience 
processing in CHR individuals8, 11, the extent to which these findings are specific to 
the CHR subset who later develop psychosis has yet to be investigated. Our second 
aim was to address this issue by examining the relationship between activation and 
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connectivity within this circuit and the subsequent onset of a psychotic disorder. We 
therefore followed up our CHR participants to determine their clinical outcome.  
 
Our primary hypothesis was that during novelty salience processing, 
hippocampal-striatal-midbrain circuit activation would be attenuated6, 7, 11 in CHR 
individuals compared to healthy controls. We also examined how pure novelty 
salience processing altered effective connectivity in this circuit. Our second 
prediction was that these alterations would be particularly evident in the CHR 





A total of 116 participants were recruited into the study. Ethical approval was 
obtained from the National Health Service UK Research Ethics Committee, and all 
participants provided written informed consent.  
 
CHR participants (n=85) were recruited from four different clinical sites in 
England: OASIS (Outreach and Support in South London)17, part of the South 
London and Maudsley NHS Trust; CAMEO, part of the Cambridge and Peterborough 
NHS Trust; the West London Early Intervention Service; and the Coventry and 
Warwick Warwickshire Partnership NHS Trust. All participants underwent clinical 
assessments and MRI scanning at King’s College London (KCL) by two trained 
researchers (CS and BQ). CHR signs and symptoms for inclusion were assessed 
with the Comprehensive Assessment of At-Risk Mental States (CAARMS)18. 
Exclusion criteria were past/present diagnosis of psychotic disorders, 
past/present/familiar history of neurological illness, substance abuse/dependence 
according to DSM-5 criteria19 or contraindication to scanning.  
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Healthy controls (HC, n=31) were recruited from the same geographical areas 
as CHR participants. None had a personal/familial history of psychiatric/neurological 
disorder or were using prescription medication as assessed via self-report. Additional 
exclusion criteria for all participants involved self-reporting illicit substance use in the 
week prior to scanning or alcohol use in the 24 hours prior to scanning.  
 
Clinical Measures 
On the day of the MRI scan, the following measures were collected at KCL by trained 
raters: psychopathology using the CAARMS18, anxiety and depression symptoms 
using the Hamilton Anxiety and Depression Scales (HAM-A/HAM-D) 20, Premorbid IQ 
was estimated with the National Adult Reading Test (NART)21. Handedness was 
assessed using the Annett Handedness Scale22. Participants provided information on 
tobacco (cigarettes/day), alcohol (units/day), and cannabis use (0=no use, 
1=experimental use, 2=occasional use, 3=moderate use, 4=severe use).  
 
Novelty Salience Task 
All participants underwent fMRI scanning on a 3T GE scanner at KCL using an 
event-related novelty salience task adapted from Bunzeck and Duzel15. Participants 
completed three 6-min runs of a visual oddball paradigm (Figure 1A). In each of the 
three runs, there were 80 standards (same picture in 73% of trials), 10 target 
oddballs (same picture in 9% of trials, requiring a button press at each presentation), 
10 neutral oddballs (same picture in 9% of trials), and 10 novel oddballs (a unique 
picture in 9% of trials representing a “pure novel stimulus”15), yielding a total of 360 
stimuli across the entire 18-min experiment (240 standards, 30 target oddballs, 30 
neutral oddballs and 30 novell oddballs). All pictures depicted black-and-white 
outdoor scenes. 
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The target stimulus, used solely to assess engagement with the task as in the 
original study15 (there was no measure of accuracy during novelty processing), was 
presented at the start of the experimental session for 4.5s. Participants were asked 
to press a button with their right index finger every time it appeared (30 presentations 
in total). During the experiment, pictures were presented for 500ms followed by a 
white fixation cross on a gray background with an inter-stimulus interval of 2.7s, 
jittered between -300ms and +300ms (uniformly distributed).  
 
Clinical Follow-Up  
The entire CHR sample was followed up subsequent to scanning to determine 
clinical outcome (transition/non-transition to psychosis). The mean interval between 
baseline and follow-up assessments was 59.7 months (SD=15.4 months). Transition 
to psychosis was determined using CAARMS Psychosis Threshold criteria18 and 
confirmed with the Structured Clinical Interview for Diagnosis19, administered by a 
psychiatrist trained in its use.  
 
Image Acquisition and Preprocessing 
See Supplement for details on fMRI acquisition and preprocessing. 
 
Statistics 
Demographic, clinical and behavioral data 
Analyses of demographic data were performed in SPSS 24 (http://www-
01.ibm.com/software/uk/analytics/spss/). The effect of group on these measures was 
examined using independent samples t-tests for parametric data and Chi-square 
tests for non-parametric data. To examine the relationship between fMRI activation 
and transition to psychosis, the CHR sample was divided into two groups at follow-
up: a transition to psychosis group (CHR-T) and a non-transition to psychosis group 
(CHR-NT). Analysis of behavioral data were performed in SPSS 24 for reaction time 
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(RT), target recognition and error rates using separate two-sample t-tests:  HC vs. 
CHR and CHR-NT vs. CHR-T. Significant effects are reported at P<0.05 with 
Bonferroni post-hoc correction as appropriate (demographic data: age, sex, IQ, years 
of education, handedness, tobacco, alcohol, cannabis, antipsychotics and 
antidepressant use – p<0.05/10 = p<0.005; clinical data: CAARMS positive, negative, 
total, GAF, HAM-A and HAM-D – p<0.05/6 = p<0.008; behavior: targetness, errors 
and RT – p<0.05/3 = p<0.017).  
 
fMRI data analysis 
Statistical analysis of the fMRI data was conducted using the general linear model in 
SPM12. Separate regressors of interest were specified for each trial type: Standard, 
Target, Neutral and Novel. Realignment parameters (x, y, z, pitch, roll, yaw) were 
included in all first-level models as covariates of no interest to account for variance 
associated with head movement. All regressors were convolved with a canonical 
hemodynamic response function during the 500ms in which trials were presented. 
One contrast image was generated for each participant to examine activation related 
to pure stimulus novelty by contrasting all novel oddball trials against neutral oddball 
trials15 and was then submitted to second-level analysis. 
 
For between-group comparisons between HC and CHR participants, a two-
sample t-test was performed using the first-level novel>neutral contrast images, 
covarying for age. We used an initial cluster defining threshold of P<0.001 
uncorrected to then enforce a voxel-wise height threshold of family-wise error (FWE) 
P<0.05 after small volume correction (SVC) for region-of-interest (ROI) analyses,23, 24 
using a pre-specified bilateral mask comprising the hippocampus, striatum and 
midbrain. The striatum was chosen on the basis of its role in the aberrant salience 
hypothesis2 and previous fMRI studies documenting salience–related responses in 
this region25. The hippocampus was chosen based on preclinical evidence for its 
Modinos et al. 
	 9 
central role in psychosis through the regulation of dopamine signaling,4 and prior 
work indicating a relationship between aberrant hippocampal activity and the CHR 
state(e.g.,26, 27). The midbrain was chosen since novel stimuli are associated with fMRI 
activations in this region as shown by Bunzeck and Duzel’s study using this task in 
healthy volunteers15. The ROI mask was built using the WFU_Pitckatlas toolbox and 
comprised predefined anatomical masks of the striatum (caudate, pallidum, 
putamen) and the hippocampus from the automated anatomical labelling atlas, and a 
6-mm sphere around the midbrain (ventral tegmental area/substantia nigra, VTA/SN) 
coordinates reported in the study with healthy volunteers15 (only right-sided as in 
Bunzeck & Duzel15, xyz: 8, -20, -18) (Figure 1B). 
 
To investigate the relationship between functional activation in response to 
novelty and transition to psychosis, a two-sample t-test was specified in SPM (CHR-
NT vs CHR-T), adjusting for age. The same ROI mask and significance threshold as 
above were applied (PFWE<0.05 after SVC). Potential confounding effects of 
substance use (alcohol, tobacco, cannabis) and levels of anxiety/depression (HAM-
A/HAM-D) on the regions showing significant novelty-related group differences were 
examined with an additional ANCOVA in SPSS. Exploratory whole-brain voxel-wise 
analysis of fMRI data (comparing all CHR to HC subjects and CHR-NT to CHR-T 
subjects) is reported in the Supplement. 
 
Dynamic Casual Modeling (DCM) 
Volumes of interest and time-series extraction 
Based on preclinical evidence4, 5 and data from a previous study of the task in 
healthy volunteers15, we used DCM12 in SPM12 to compute effective connectivity 
within a circuit comprising the hippocampus, the striatum and the midbrain (Figure 
3A). The volumes of interest (VOIs) for these regions were defined using the 
maximally activated coordinates in the second-level fMRI analysis within our masked 
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regions (Figure 1B), following published rules for the application of DCM28. The VOI 
for the hippocampus was extracted from the group-level fMRI difference between 
CHR versus HCs (xyz: 38 -16 -14). As there was no significant group-level difference 
in either the striatum or midbrain, we used the coordinates of the task effect of 
novel>neutral across all participants with an 8-mm sphere for each region, allowing 
the center of the sphere to move to the nearest supra-threshold voxel (xyz: striatum, 
28 20 -2; VTA/SN, 14 -24 -16; PUNC<0.05). 
  
Group comparisons with parametric empirical Bayes (PEB) 
PEB, included in SPM12, allows evaluating group effects and between-subjects 
variability on DCM parameters (HC vs CHR; CHR-NT vs CHR-T). PEB for DCM is 
performed by comparing the posterior density of any (reduced) model in terms of the 
posterior of its parent or full model. The first step is to estimate a full model (i.e., with 
every connection switched ‘on’) for every subject. Then, a nested model is 
constructed (i.e., with certain conditions switched ‘off), which allows the expression of 
the posterior density of any (reduced) model in terms of the posterior of its parent or 
full model. This process affords an efficient way to evaluate posterior densities under 
empirical priors. It is then possible to apply Bayesian model reduction to the posterior 
densities over the second-level parameters to find out where between-subject effects 
are expressed.29 Results are given by the group effect on the Posterior Probabilities 
(P) and the Bayesian Confidence Interval. Group differences were thresholded with a 
P>0.5 obtained as recommended by DCM’s developers 
(https://arxiv.org/pdf/1902.10604.pdf) and following Kass & Raftery.30 Although 
comparing Bayes Factor to P-values is not straightforward, it could be argued that it 
is equivalent to P<0.05.31 The present study examined how the connections between 
the anterior hippocampus, ventral striatum and VTA/SN were modulated by stimulus 
novelty (novel>neutral oddball trials) by generating a second model space which 
included a full model, to then create four different models with each connection 
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switched ‘off’ (nested models) (Figure 3A). Group differences were then verified by 
comparing the evidence between the full model and the nested model. Group 
variables were de-meaned before being entered in the PEB model, to account for the 
different sample sizes of our study groups. Age was included as a covariate on all 
PEB analyses.  
 
Additional exploratory analyses within the CHR group and its subgroups 
according to transition status were conducted to examine potential associations 
between severity of positive prodromal symptoms and fMRI response to novelty / 
DCM connectivity strengths (eFigure 1 in Supplement).  
 
RESULTS 
Demographic and clinical data 
Nine CHR participants were excluded from the final analyses due to incomplete fMRI 
data (n=3), or excessive movement (n=6). The analyzed sample thus comprised 76 
CHR participants and 31 HCs. Detailed examination of potential movement 
confounds is reported in the Supplement (eTable 1 and eFigure 2).  
 
All of the CHR participants met the CAARMS Attenuated Psychotic 
Symptoms criteria32. A minority additionally fulfilled the BLIPS (n=5) or schizotypal 
personality disorder/familial risk criteria (n=2). At the time of scanning, most (67/76; 
88%) CHR participants were naïve to antipsychotic medication. The remainder were 
taking low doses of antipsychotics (<1.5mg haloperidol equivalents per day). The 
majority of CHR participants were also anti-depressant free at the time of scanning 
(48/76; 63%). 
 
 The HC and CHR groups did not differ significantly in gender, handedness, 
estimated IQ, years of education, alcohol, or cannabis use. However, the CHR group 
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was younger and smoked more tobacco. As would be expected, they showed higher 
levels of anxiety and depressive symptoms (HAM-A/HAM-D scores) and had lower 
levels of overall functioning compared to HCs (GAF score) (Table 1). 
 
Thirteen of the CHR participants (17%) developed a psychotic disorder within 
the follow-up period of 59.7 months (CHR-T), while 63 participants did not (CHR-NT). 
There were no significant differences in demographic or clinical variables at baseline 
between these groups (Table 1). 
 
Behavioral Data 
The groups did not differ in their engagement with the fMRI task (mean RT or 
recognition of target stimuli; eTable 2 in the Supplement). 
 
fMRI data 
Effect of task 
Across groups, pure stimulus novelty was associated with activation in the anterior 
hippocampus, ventral striatum and midbrain bilaterally (PFWE<0.05 after SVC; Table 
2, Figure 2A).  
 
Group differences: all CHRs vs HCs  
In CHR participants, relative to HC, pure stimulus novelty (novel>neutral oddball trial) 
was associated with significantly less activation in the anterior portion of the right 
hippocampus than in HCs (PFWE=0.041; xyz=38 -16 -14; Z=3.42, Hedges’ g=0.543; 
Figures 2B/2C). There were no areas where CHR participants showed greater 
activation than HC. These findings remained unchanged after adding sex as 
additional covariate of no interest in the analysis (HC > CHR: right hippocampus, 
PFWE=0.033; xyz=38 -16 -14; Z=3.49, Hedges’ g=0.544; CHR > HC no 
suprathreshold voxels). 




Because resting-state neuroimaging studies in CHR groups have reported 
increased hippocampal perfusion/metabolism26, 27, 33, 34, we tested whether the 
reduced activation of the right anterior hippocampus in CHR relative to HC during 
pure stimulus novelty reflected an increased response to the neutral comparator 
stimuli that fMRI studies traditionally use35. This supplementary analysis involved the 
contrast of neutral oddballs versus standards, reflecting activation related to 
unexpected, as opposed to novel stimuli, and revealed an increased hippocampal 
response in CHR relative to HC at a lenient threshold (P=0.004 uncorrected, x y 
z=36 -24 -16; kE = 20; z = 2.66; Hedges’ g=0.186; Figure 1). 
 
Group differences: transition to psychosis  
There were no significant differences in activation between the CHR-T subgroup and 
either the CHR-NT subgroup or HCs. However, as in the total CHR sample, a lower 
right anterior hippocampal response to novel>neutral stimuli was evident when CHR-
NT were compared with HC (PFWE=0.018; xyz=38 -16 -14; Z=3.68, Hedges’ g=0.626). 
These findings remained unchanged after additionally adjusting the analysis for sex 
(HC > CHR-NT: right hippocampus, PFWE=0.013; xyz=38 -16 -14; Z=3.76, Hedges’ 
g=0.488; HC <> CHR-T or CHR-NT <> CHR-T: no suprathreshold voxels). Clinical 
follow-up information (transition/non-transition) was not available for 6 of the 76 CHR 
individuals; repeating the transition analysis with these 6 individuals excluded from 
the CHR-NT group did not change the results (HC > CHR-NT: right hippocampus, 
PFWE=0.019; xyz=38 -16 -14; Z=3.64, Hedges’ g=0.621; HC <> CHR-T or CHR-NT 
<> CHR-T: no suprathreshold voxels). 
 
Analysis of potential confounders 
A secondary analysis assessed the potentially confounding effects of substance use 
(alcohol, cigarettes and cannabis) and levels of anxiety/depression (HAM-A/HAM-D) 
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on the group difference in right anterior hippocampus activation. The group effect 
remained significant (F1,80=5.486, P=0.022, Hedges’ g=0.742) (eTable 3 in the 
Supplement). We also examined whether antipsychotic medication could have 
affected the results by repeating the analysis after the 9 CHR participants who were 
receiving antipsychotics had been excluded from the SPM design. Again, the group 
difference in the right anterior hippocampus remained significant (PFWE=0.042; 
xyz=38, −18 −14; Z=3.43, Hedges’ g=0.591). Finally, comparing CHR participants 
with (n=28) versus CHR participants without (n=48) antidepressants showed no 
suprathreshold effects at PFWE<0.05. 
 
Exploratory whole-brain fMRI results (comparing all CHR with HC subjects and CHR-
NT with CHR-NT subjects) are reported in the Supplement (eTable 4, eFigure 3). 
 
Effective connectivity: all CHRs vs HCs  
For the comparison of HC vs CHR groups, PEB revealed group differences in the 
modulatory effect of pure stimulus novelty on hippocampal-striatal-midbrain 
connections. The CHR group showed relatively reduced connectivity from VTA/SN to 
striatum (P:0.52), but greater connectivity from hippocampus to striatum (P:0.64) and 
from VTA/SN to hippocampus (P:0.68) (Figure 3B). These findings remained largely 
unchanged after additionally adjusting the analysis for sex (VTA/SN to hippocampus 
P:0.74; hippocampus to striatum P:0.63; although VTA/SN to striatum P:0.47). 
 
Effective connectivity: transition to psychosis  
Comparison of the CHR participants who subsequently developed psychosis and 
those who did not by PEB analysis also revealed a group difference: the CHR-T 
subgroup showed reduced connectivity from VTA/SN to striatum compared to the 
CHR-NT subgroup (P:0.51) (Figure 3C). This finding remained unchanged after 
additionally adjusting the analysis for sex (P:0.53). Repeating this analysis excluding 
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the 6 individuals for which follow-up clinical information was not available revealed 
that the reduced connectivity in CHR-T individuals from VTA/SN to striatum remained 
significant (P:0.71), and a further connectivity decrease was observed for the 
backward connection from the striatum to the VTA/SN (P:0.75) (eFigure 4).  
 
DISCUSSION 
Our first major finding was that participants at CHR for psychosis showed an altered 
anterior hippocampal response during pure stimulus novelty processing, suggesting 
that salience dysregulation is not only present in patients with psychosis, but is also 
evident before its onset. The result was not attributable to effects of age, treatment 
with antipsychotic or antidepressant medication, substance use, anxiety/depression 
symptoms, or differential behavioral engagement with the fMRI task. Complementary 
whole-brain analysis showed no significant between-group differences (as shown in 
the Supplement), suggesting that during ‘pure stimulus novelty’ processing regions 
outside our a priori hippocampal-striatal-midbrain mask would not be differentially 
engaged by CHR individuals. The second major finding came from applying a circuit-
based approach to examine functional coupling within a hippocampus–striatal–
midbrain circuit during salience processing. CHR subjects showed significantly 
reduced effective connectivity from the midbrain to the striatum compared to controls, 
but greater connectivity from the hippocampus to the striatum and from the midbrain 
to the hippocampus. The reduction in midbrain-striatal connectivity in the whole 
sample was also evident in the subgroup who later became psychotic compared to 
the subgroup who did not. Overall, the results support previous reports that altered 
salience-related response in the hippocampus is associated with psychosis risk,8, 11 
and suggest that the subsequent development of psychosis may rather be based on 
circuit-based connectivity disruptions. 
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According to a well-validated neurodevelopmental animal model, the 
methylazoxymethanol acetate (MAM) model, increased tonic activity of the 
ventral/anterior hippocampus leads the ventral striatum to disinhibit the midbrain via 
inhibition of the ventral pallidum, which increases the number of spontaneously 
active midbrain dopamine neurons4, 36. Human imaging evidence has been largely 
consistent with this model37. Resting cerebral blood volume (CBV) or flow (CBF) is 
elevated in the anterior hippocampus of patients with schizophrenia33, 34, 38, 39 and 
CHR individuals26, 27, 34. Higher levels of CBV/CBF are positively associated with 
psychotic symptoms in CHR subjects33 and with subclinical psychotic-like 
experiences in schizotypal individuals40. Furthermore, CHR subjects show elevated 
striatal dopamine function41, 42, an association between striatal dopamine function 
and reduced hippocampal activation during a memory task43, and altered 
hippocampal glutamate levels44, 45. In turn, altered hippocampal glutamate levels 
have been related to abnormal hippocampal activation during a memory task in 
CHR46. Our findings extend this literature by showing that hippocampal dysregulation 
is also evident when CHR individuals process novelty salience.  
 
An important consideration in the interpretation of fMRI data is that increases 
and decreases in BOLD response depend on (i) the direction of the change in 
regional brain activity relative to the baseline for both the control and the task 
condition, (ii) the way in which the control condition and the condition of interest are 
compared, (iii) comparing groups which may have different baseline states35, 47. Our 
novelty salience paradigm was adapted from that employed by Bunzeck and Duzel15 
showing that the VTA/SN preferentially responds to stimulus novelty over other forms 
of stimulus salience. The contrast between novel and neutral oddballs allowed 
quantification of neural response to what the authors called “pure stimulus novelty”, 
as opposed to rareness/deviance per se15. Our results suggest that the reduced 
response to pure stimulus novelty in the right anterior hippocampus in CHR 
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individuals may be driven by increased response to the control condition comprising 
neutral stimuli (albeit at an uncorrected level).  
 
In terms of effective connectivity within this circuit, relative to controls, CHR 
subjects showed greater modulation by pure stimulus novelty in the connection from 
hippocampus to striatum and from midbrain to hippocampus. While this analysis also 
indicated reduced modulation of connectivity from midbrain to striatum in CHR 
individuals, this effect was no longer significant once sex was adjusted for in the 
analysis, suggesting a potential relationship between midbrain-striatal connectivity 
and sex in the CHR state which merits further research. Overall, these findings 
suggest that, in CHR subjects, afferent and efferent connectivity of the hippocampus 
were increased, consistent with disrupted interactions within a hippocampal-striatal-
midbrain circuit being associated with increased risk for psychosis. This pattern of 
dysconnectivity would be in line with the maximal tonic activation of dopamine 
neuron firing hypothesized to occur in psychosis, thought to obscure salience-driven 
increases in population activity of mesostriatal dopamine neurons36, leading to all 
stimuli being inappropriately registered as salient. This could account for the 
increased response to non-novel stimuli, and the attenuation of the hippocampal 
response to salient stimuli, observed in the CHR group.  
 
Although the later onset of psychosis in CHR subjects was not associated 
with significant differences in hippocampal activation, this subgroup showed reduced 
modulation by pure stimulus novelty of the effective connectivity from midbrain to 
striatum compared to CHR subjects who did not become psychotic. As a similar 
alteration in midbrain-striatal connectivity was also evident in the total CHR sample 
relative to controls (above), this suggests that among the changes in connectivity 
seen in the CHR sample, alterations in communication from midbrain to striatum may 
be particularly relevant to the subsequent onset of psychosis. This would be 
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consistent with PET studies in CHR subjects showing elevated midbrain and striatal 
dopamine function linked to later transition to psychosis42, 43. An alternative 
explanation relates to a ‘ceiling effect’ for hippocampal activity and subcortical 
connectivity in dopamine-related regions; the lower hippocampal response to novel 
versus non-novel stimuli could reflect a reduced signal-to-noise ratio in the 
comparison between these two conditions in CHR individuals, supported by the 
(uncorrected) hyper-responsivity to the neutral comparator condition. This notion is 
consistent with previous findings on emotional salience in CHR groups that lower 
responses to emotional stimuli are driven by increased responses to the neutral, non-
emotional condition48-52, and by reports of increased resting hippocampal perfusion in 
CHR26, 27, 33, 34. Taken together, these results suggest that increased baseline 
activity/tonic dopamine signaling within this circuitry may render CHR/CHR-T 
individuals less able to 'effectively' distinguish between novel (salient) and non-novel 
(non-salient) stimuli.  
 
Despite studying a relatively large sample of CHR subjects, the number in the 
CHR-T subgroup was small; the findings in this subgroup should therefore be 
interpreted with caution, and warrant replication in larger samples. Previous imaging 
studies of salience processing in CHR individuals relative to HCs have found 
significant differences in activation of the hippocampal-striatal-midbrain circuit in the 
context of reward/motivational salience8, 11, but not novelty or emotional salience. A 
possible explanation for this discrepancy might relate to modest sample sizes in 
previous studies, as we included a relatively large CHR sample (n=76). Additional 
sources for discrepancies might relate to the use of different salience task 
paradigms, tapping on different dimensions of salience processing. More specifically, 
Roiser et al.11 used the Salience Attribution Task (SAT), a monetary reward task 
measuring adaptive and aberrant motivational salience. In contrast, Winton-Brown et 
al.8 used the Salience Integration Task (SIT), a monetary incentive delay task in 
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which conditions were manipulated to examine reward (monetary), novelty (with half 
of the trials as pre-familiarized and the other half as novel), and aversion (with half of 
the pictures as emotionally aversive). Given that salience is a multifaceted 
construct12, and that novelty salience had not been studied in relation to transition to 
psychosis, we used a task paradigm known to robustly isolate the specific processing 
of novelty15. In terms of findings, Roiser et al. focused on the dorsolateral prefrontal 
cortex, hippocampus and midbrain, and found that the magnitude of aberrant 
motivational salience attribution was positively correlated with ventral striatal 
responses to non-salient cue features11. Winton-Brown et al. focused on the 
hippocampus, striatum and midbrain, and found significant group differences with 
CHR subjects showing greater activation than HC to reward-predicting stimuli in the 
ventral pallidum and in the midbrain/hippocampus, while they did not observe any 
significant effects for novelty or emotional salience8. In the present study, using a 
specific ‘pure stimulus novelty’ salience task, we observed a significant difference in 
hippocampal responsivity between HC and CHR individuals. Finally, Roiser et al.11 
had shown an abnormal association between hippocampal response to motivational 
salience and dopamine synthesis capacity in a smaller sample of CHR individuals. 
Given that the hippocampus is central to the processing of novelty salience,53 it 
would be interesting to determine whether the hippocampal alteration we detected 
during novelty processing is also abnormally associated with dopamine synthesis 
capacity in CHR individuals. 
 
In summary, the data from the present study indicate both perturbed 
hippocampal activation and hippocampal-striatal-midbrain effective connectivity in 
the context of novelty salience in people at CHR for psychosis, and that the later 
onset of psychosis is associated with alterations in midbrain-striatal connectivity. 
These findings are consistent with data from preclinical models of psychosis 
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implicating alterations in a hippocampal–striatal-midbrain circuit in the development 
of psychosis.  
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Figure 1. (A) Task paradigm. (B) Region-of-interest mask used for small volume 
correction on the fMRI analysis. Red = hippocampus; green = striatum; blue = 
midbrain. L = left hemisphere; R = right hemisphere. 
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Figure 2. (A) Novel > Neutral oddball trials across groups, and (B) Between-group 
clinical high risk (CHR) versus healthy control (HC) results in right hippocampus for 
the contrasts of novel > neutral oddballs with activation superimposed on a standard 
T1 template. (C) Boxplots show mean hippocampal activation in each group for novel 
> neutral (pure stimulus novelty) and neutral > standard (stimulus 
rareness/deviance). L = left hemisphere; R = right hemisphere. 
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Figure 3. (A) DCM model. (B) Group effects on PEB models between HC and CHR. 
(C) Group effects on PEB models between CHR-NT and CHR-T. Gray bars show 
posterior probabilities for model evidence. Pink bars represent the Bayesian 95% 
confidence interval. 
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TABLES 









g or V P 
Age (years) 25.0 (4.1) 22.46 
(3.6) 
0.677 0.003 22.7 (3.8) 21.9 (2.6) 0.220 0.488 
Gender (male/female) 15/16 42/34 0.063 0.518 36/27 6/7 0.083 0.468 




0.097 0.669 103.6 
(15.6) 
103.1 (8.2) 0.034 0.878 
Years of education 15.8 (3.5) 14.6 (2.2) 0.455 0.071 14.6 (2.2) 14.5 (2.5) 0.044 0.907 
CAARMS         
Positive score - 10.1 (4.1) -  9.7 (3.9) 11.8 (4.7) 0.520 0.102 
Negative score - 5.1 (4.1) -  5.1 (4.1) 4.8 (4.3) 0.073 0.785 
Total score - 42.3 
(22.4) 
-  42.1 (21.9) 43.2 (25.5) 0.050 0.873 
GAF score 92.9 (5.0) 58.0 (9.5) 4.124 <0.001 58.5 (9.7) 55.3 (8.5) 0.336 0.272 
HAM-A score 3.4 (4.2) 18.4 
(11.2) 
1.542 <0.001 17.5 (10.4) 22.8 (14.2) 0.477 0.173 
HAM-D score 1.7 (3.5) 17.6 
(11.1) 
1.662 <0.001 17.0 (11.1) 20.3 (11.2) 0.297 0.396 
Tobacco 
(cigarettes/day) 
1.9 (3.4) 6.3 (9.0) 0.563 0.001 7.2 (9.6) 2.1 (3.6) 0.573 0.074 
Alcohol (units/day) 1.7 (2.2) 1.6 (3.4) 0.032 0.964 1.8 (3.6) 0.9 (0.7) 0.272 0.426 
Cannabis (median 
[range])a 
0 [0-3] 0 [0-4] 0.146 0.703 0 [0-4] 0 [0-4] 0.147 0.811 
Antipsychotic 
medication (n) 
- 9 (12%) - - 8 (13%) 1 (8%) 0.058 0.611 
Antidepressant 
medication (n) 
1 (3.2%) 28 (37%) 0.343 <0.001 25 (40%) 3 (23%) 0.130 0.258 
Right-handed (n) 26 (90%) 64 (85%) 0.187 0.162 52 (83%) 12 (92%) 0.090 0.434 
a 0=never, 1=experimental use, 2=occasional use, 3=moderate use, 4=severe use. 
CAARMS, Comprehensive Assessment for the At-Risk Mental State; CHR, clinical high risk; CHR-NT, 
clinical high-risk non-transition; CHR-T, clinical high-risk transition; GAF, Global Assessment of 
Functioning scale; HAM-A, Hamilton Anxiety Rating Scale; HAM-D, Hamilton Depression Rating Scale; 
HC, healthy controls; NART, National Adult Reading Test. g or V, Hedges’ g or Cramer’s V. 
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Table 2. Random Effects Analysis for Novel Oddballs versus Neutral Oddballs 
Across and Within Groups in the hippocampal-striatal-midbrain region of interest. 
Brain Area MNI Coordinates k T Z Voxel-
wise PFWE 
 x y z     
Across all participants 
(n=107) 
       
R anterior hippocampus 32 -12 -14 568 5.52 5.16 <0.001 
L hippocampus -26 -30 -6 560 4.77 4.53 0.001 
R midbrain 12 -24 -16 50 4.37 4.18 <0.001 
R ventral putamen 28 20 -2 963 5.91 5.47 <0.001 
R dorsal pallidum 18 4 6  4.25 4.07 0.008 
R ventral caudate 14 8 6  4.15 3.98 0.012 
L ventral putamen -26 14 -4 540 4.28 4.10 0.008 
HC (n=31)        
R anterior hippocampus 32 -14 -14 542 4.89 4.62 <0.001 
L hippocampus -22 -34 -6 552 3.96 3.82 0.011 
R midbrain 14 -18 -14 5 3.22 3.13 0.014 
R ventral putamen 32 4 -8 42 3.77 3.64 0.019 
CHR (n=76)        
R hippocampus 22 -32 -2 18 3.63 3.51 0.031 
R midbrain 12 -24 -16 24 4.00 3.85 0.002 
R ventral putamen 28 20 -2 247 5.57 5.20 <0.001 
L ventral putamen -26 14 -6 19 3.68 3.56 0.024 
CHR-NT (n=63)        
R midbrain 12 -24 -16 17 3.59 3.48 0.005 
R ventral putamen 28 20 -2 124 5.43 5.08 <0.001 
CHR-T (n=13)        
No suprathreshold voxels        
L, left; R, right. CHR, clinical high risk; CHR-NT, clinical high-risk non-transition; CHR-T, 
clinical high-risk transition; HC, healthy controls. 
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fMRI acquisition and preprocessing 
Echo-planar images sensitive to blood oxygenation level-dependent (BOLD) contrast 
were acquired to measure hemodynamic responses on a General Electric Signa HDx 
TwinSpeed 3T scanner (Milwakee, Wisconsin) at the Centre for Neuroimaging 
Sciences, Institute of Psychiatry, Psychology & Neuroscience (King’s College 
London). Acquisition parameters were as follows: repetition time (TR): 2000 ms; 
echo time (TE), 30 ms; flip angle, 75°; slice thickness, 3 mm; field of view (FoV), 240; 
39 axial sections collected with sequential (top-down) acquisition and 3.3-mm 
interslice gap). Structural data were acquired by means of a three-dimensional T1-
weighted magnetization prepared rapid acquisition gradient-echo sequence (TR = 
6.98 ms, TE = 2.85 ms, voxel size = 1.05 × 1.05 × 1.2 mm, FoV = 260 mm, flip angle 
= 11°, inversion time = 400 ms). Three clinical high risk (CHR) subjects had to be 
excluded because of failure to complete the fMRI task. Functional MRI data were 
preprocessed using the SPM12 software 
(http://www.fil.ion.ucl.ac.uk/spm/software/spm12). After slice timing, realignment, 
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segmentation, co-registration and stereotaxic normalization (2x2x2 mm3), images 
were spatially smoothed using an 8-mm full-width at half-maximum Gaussian filter 
and a high pass filter (128 s). Excessive movement was considered at 43 mm of 
translation and 3 degrees of rotation in any axis; six clinical high risk (CHR) subjects 
exceeded this threshold and were therefore removed from the final analysis. 
 
Results 
Relationship between pure stimulus novelty activation / DCM connectivity and 
psychotic symptoms 
Exploratory correlations between fMRI parameter estimates extracted from regions 
showing significant novelty-related group differences and severity of positive 
prodromal symptoms (summary scores of CAARMS unusual though content, non-
bizarre ideas, perceptual abnormalities and disorganized speech) were tested with 
Pearson correlation analysis in SPSS. Within the CHR-T group, activation 
parameters in the right anterior hippocampus during novelty processing were 
significantly negatively correlated with CAARMS positive symptoms (r=-0.652, 
p=0.016) (eFigure 1). There were no significant correlations in the CHR group as a 
whole (r=-0.115, p=0.324) or in the CHR-NT group (r=-0.055 p=0.671).  
 
 
eFigure 1. Scatterplots depicting a significant inverse correlation between right 
hippocampal response to Neutral > Standard and severity of CAARMS positive 
symptoms within CHR-T the group (left), which was absent in the CHR-NT group 
(middle) and the CHR group as a whole (right). 
 




Finally, correlations between severity of positive symptoms and connectivity 
strengths were assessed with using a PEB model with the CAARMS positive 
symptom as a regressor. PEB results of this type of analysis results in estimation of 
the effect size and probability for that effect. For this analysis, we included only the 
CHR sample. We have thresholded results at P>0.5 (weak probability). In the total 
CHR sample, there was a positive effect between the strength of modulation of the 
forward connection from the VTA/SN to the hippocampus and the severity of 
CAARMS positive symptoms (effect size: 0.04; P: 0.57), and a negative association 
between connectivity from the hippocampus to the striatum and CAARMS positive 
symptoms (effect size: -0.07; P: 0.69). The negative effect between hippocampus to 
striatum connectivity and positive symptoms was also evident in CHR-NT subjects 
(Effect size: -0.06 P: 0.66). In the CHR-T group, there were effects of CAARMS 
positive symptoms in VTA/SN to Striatum (effect size: -0.05; P: 0.55) and in VTA/SN 
to hippocampus (effect size: 0.09; P:0.72). 
 
Examining Potential Movement Confounds 
We used movement parameters for each trial in each of the three runs for each 
subject to compare movement between groups. For the final sample of 31 healthy 
controls (HC) and 76 CHR subjects (of which 13 became CHR-T and 63 CHR-NT), 
mean incremental (frame-to-frame) movement and group t-test results for each 
translation axis (x, y, z) and rotation axis (pitch, roll, yaw) averaged across the three 
task runs are summarized in eTable 1. 
 HC (n=31) CHR (n=76)   CHR-NT 
(n=63) 
CHR-T (n=13)   
 Mean SE Mean SE g p Mean SE Mean SE g p 
x 0.0042 0.11 0.0167 0.14 0.095 0.662 0.0264 0.14 -0.0305 0.14 0.406 0.189 
y -0.0316 0.16 0.0051 0.15 0.240 0.273 0.0076 0.14 -0.0087 0.22 0.105 0.752 
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eTable 1. Incremental movement. 
* P < 0.05. g, Hedges’ g. 
 
There was a difference between HC and CHRs in the yaw dimension (p = 0.034); 
therefore, movement parameters (x, y, z, pitch, roll, yaw) were included in all first 
level fMRI models as covariates of no interest to rule out variance associated with 
head movement. There were no significant differences between HC and CHRs in any 
of the other axis/dimensions, as well as no significant differences in any of the 
movement parameters between CHR-NT and CHR-T. 
eFigure 2: Violin plots showing mean incremental (frame-to-frame) movement by 
each translation (x, y, z: 1A and 2A) and rotation axis (pitch, roll, yaw: 1B and 2B) 
z 0.1357 0.34 0.1414 0.30 0.018 0.931 0.1285 0.31 0.2036 0.25 0.249 0.412 
pitch -0.0003 0.01 0.0004 0.01 0.07 0.679 0.0003 0.01 0.0005 0.01 0.02 0.935 
roll 0.0001 0.00 0.0003 0.00 0.07 0.852 0.0003 0.00 0.0000 0.00 0.02 0.720 
yaw -0.0004 0.00 0.0005 0.00 0.07 0.034* 0.0004 0.00 0.0006 0.00 0.02 0.808 
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averaged across the 3 task runs by group (HC vs CHR total, 1A and 1B; CHR-NT vs 




Reaction time (RT) 
Behavioral analysis of RTs revealed that mean reaction times (RT) did not differ 
significantly between the groups (eTable 2). 
 
Target recognition 
Target stimuli detection was nearly perfect across all participants, with a mean hit 
rate >95% and a very low error rate of <7%, with no significant between-group 
differences (eTable 2).  
 










Targetness (%) 96.3 96.3 0.009 0.964 96.3 96.1 0.032 0.924 












Targetness = percent correct hits on target stimuli. Errors = false alarms + missed 
hits. CHR, clinical high risk; CHR-NT, clinical high-risk non-transition; CHR-T, 
clinical high-risk transition; HC, healthy controls. g, Hedges’ g. 
 
 
Analysis of potential confounders 
A univariate ANCOVA in SPSS with the individual right hippocampal parameter 
estimates of activation to Novel > Neutral as dependent variable, Group as between-
subjects factor, and alcohol use, cigarettes, cannabis use, HAM-A and HAM-D 
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scores as covariates showed that the group effect remained significant (F1,80 = 5.486, 
p = 0.022, Cohen’s d = 0.742). Further details are provided in eTable 3 below. 
 







Across groups and at the whole-brain level, pure stimulus novelty was associated 
with activation in the fusiform gyrus/occipital lobes and insula bilaterally, right 
hippocampus, putamen, inferior frontal gyrus/middle frontal gyrus, medial frontal 
gyrus and middle temporal gyrus, and with the left inferior parietal lobule (voxel-wise 
pFWE<0.05, eTable 4, eFigure 3). At the whole brain level, there were no regions that 
showed between-group differences in the CHR as a whole relative to the HC group, 
or in the CHR-NT relative to the CHR-T group. 
 
eTable 4: Random Effects Analysis for Novel Oddballs versus Neutral Oddballs 
Across and Within Groups at the Whole-Brain Voxel-wise Level. The x, y, z 
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coordinates of local maxima are listed according to the MNI coordinate system. All 
results voxel-wise p<0.05 FWE corrected. 
Brain Area MNI Coordinates k T Z Voxel-
wise 
pFWE 
 x y z     
Across all participants 
(n=107) 
       
R fusiform gyrus 28 -46 -14 4959 13.10 Inf <0.001 
R middle occipital gyrus 36 -78 9  8.33 7.27 <0.001 
R superior occipital gyrus 20 -94 -6  8.05 7.08 <0.001 
L fusiform gyrus -30 -48 -20 3730 11.69 Inf <0.001 
L inferior occipital gyrus -18 -94 -6  9.52 Inf <0.001 
L middle occipital gyrus -36 -86 -2  9.40 Inf <0.001 
R inferior frontal gyrus 44 12 28 1367 6.88 6.23 <0.001 
R middle frontal gyrus 48 32 22  6.41 5.87 <0.001 
L insula -30 22 -2 388 6.64 6.05 <0.001 
R insula 32 22 -2 613 6.63 6.04 <0.001 
R hippocampus 32 -12 -14  5.52 5.16 0.002 
R putamen 32 4 -8  5.24 4.93 0.004 
L inferior parietal lobe -28 -58 42 130 6.09 5.62 <0.001 
R medial frontal gyrus 8 30 42  5.70 5.30 0.001 
R middle temporal gyrus 58 -40 -10 20 5.35 5.02 0.003 
R middle frontal gyrus 40 46 14 23 4.91 4.65 0.015 
HC (n=31)        
R fusiform gyrus 30 -48 -16 1114 7.79 6.90 <0.001 
R calcarine gyrus 20 -94 -6  5.90 5.47 <0.001 
L fusiform gyrus -32 -50 -20 971 4.82 6.56 <0.001 
L lingual gyrus -30 -82 -16  4.97 4.70 0.012 
L middle occipital gyrus -16 -92 -6 455 7.23 6.49 <0.001 
L inferior occipital gyrus -28 -92 -8  5.39 5.05 0.003 
R middle occipital gyrus 36 -78 8 71 5.00 4.73 0.011 
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R hippocampus 32 -14 -14 7 4.89 4.63 0.016 
R inferior frontal gyrus 54 20 30 5 4.74 4.50 0.026 
CHR (n=76)        
R fusiform gyrus 28 -46 -14 3809 12.13 Inf <0.001 
R middle occipital gyrus 34 -72 20  8.25 7.22 <0.001 
L fusiform gyrus -30 -48 -16 2912 10.23 Inf <0.001 
L middle occipital gyrus -34 -88 -2  8.48 7.37 <0.001 
R inferior frontal gyrus 44 12 30 954 6.68 6.08 <0.001 
R insula 36 20 -4 622 6.58 6.00 <0.001 
L insula -28 24 0 415 6.57 5.99 <0.001 
R medial frontal gyrus 8 28 42 44 5.01 4.73 0.011 
L inferior parietal lobe -30 -56 40 26 4.99 4.72 0.011 
CHR-NT (n=63)        
R fusiform gyrus 28 -46 -14 3363 10.93 Inf <0.001 
R middle occipital gyrus 34 -72 20  7.94 7.00 <0.001 
L fusiform gyrus -30 -48 -18 1266 9.05 7.74 <0.001 
L middle occipital gyrus -34 -88 -2 1109 8.21 7.18 <0.001 
L inferior occipital gyrus -20 -94 -8  6.41 5.86 <0.001 
R insula 34 20 -4 405 6.04 5.58 <0.001 
R inferior frontal gyrus 40 8 30 378 5.78 5.37 0.001 
R middle frontal gyrus 42 30 20 175 5.55 5.18 0.001 
R medial frontal gyrus 10 24 42 16 4.79 4.54 0.021 
CHR-T (n=13)        
R fusiform gyrus 30 -44 -14 170 5.45 5.10 0.002 
L cerebellum lobule 6 -36 -54 -24 124 4.95 4.68 0.012 
L fusiform gyrus -32 -48 -16  4.91 4.64 0.015 
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eFigure 3: Random Effects Analysis for Novel Oddballs versus Neutral Oddballs 
Across and Within Groups at the Whole-Brain Voxel-wise Level. (A) across groups, 
(B) within HCs, (C) within CHRs, (D) within CHR-NT, (E) within CHR-T. Activation 
maps are superimposed on a standard T1 template. All results voxel-wise p<0.05 
FWE corrected. L = left hemisphere; R = right hemisphere. 
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Effective connectivity: transition to psychosis excluding CHR subjects for whom 
clinical outcome information could not be obtained 
 
eFigure 4. (A) DCM model. (B) Group effects on PEB models between CHR-NT 
(n=57) and CHR-T (n=13). Gray bars show posterior probabilities for model 
evidence. Pink bars represent the Bayesian 95% confidence interval. 
 
